These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17600705)

  • 1. N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics.
    Bamborough P; Angell RM; Bhamra I; Brown D; Bull J; Christopher JA; Cooper AW; Fazal LH; Giordano I; Hind L; Patel VK; Ranshaw LE; Sims MJ; Skone PA; Smith KJ; Vickerstaff E; Washington M
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4363-8. PubMed ID: 17600705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel 2-(aminoheteroaryl)-thiazole-5-carboxamides as potent and orally active Src-family kinase p56(Lck) inhibitors.
    Chen P; Norris D; Das J; Spergel SH; Wityak J; Leith L; Zhao R; Chen BC; Pitt S; Pang S; Shen DR; Zhang R; De Fex HF; Doweyko AM; McIntyre KW; Shuster DJ; Behnia K; Schieven GL; Barrish JC
    Bioorg Med Chem Lett; 2004 Dec; 14(24):6061-6. PubMed ID: 15546730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular docking guided 3D-QSAR CoMFA analysis of N-4-Pyrimidinyl-1H-indazol-4-amine inhibitors of leukocyte-specific protein tyrosine kinase.
    Awale M; Mohan CG
    J Mol Model; 2008 Oct; 14(10):937-47. PubMed ID: 18626671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of N-4,6-pyrimidine-N-alkyl-N'-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase.
    Maier JA; Brugel TA; Sabat M; Golebiowski A; Laufersweiler MJ; VanRens JC; Hopkins CR; De B; Hsieh LC; Brown KK; Easwaran V; Janusz MJ
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3646-50. PubMed ID: 16682201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
    J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
    J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.
    Martin MW; Newcomb J; Nunes JJ; Bemis JE; McGowan DC; White RD; Buchanan JL; DiMauro EF; Boucher C; Faust T; Hsieh F; Huang X; Lee JH; Schneider S; Turci SM; Zhu X
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2299-304. PubMed ID: 17276681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
    J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cheng A; Faust T; Hsieh F; Huang X; Lee JH; Marshall TL; Martin MW; McGowan DC; Schneider S; Turci SM; White RD; Zhu X
    Bioorg Med Chem Lett; 2007 Apr; 17(8):2305-9. PubMed ID: 17280833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-(3-(phenylcarbamoyl)arylpyrimidine)-5-carboxamides as potent and selective inhibitors of Lck: structure, synthesis and SAR.
    Deak HL; Newcomb JR; Nunes JJ; Boucher C; Cheng AC; DiMauro EF; Epstein LF; Gallant P; Hodous BL; Huang X; Lee JH; Patel VF; Schneider S; Turci SM; Zhu X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1172-6. PubMed ID: 18083554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SVM model for virtual screening of Lck inhibitors.
    Liew CY; Ma XH; Liu X; Yap CW
    J Chem Inf Model; 2009 Apr; 49(4):877-85. PubMed ID: 19267483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lead validation and SAR development via chemical similarity searching; application to compounds targeting the pY+3 site of the SH2 domain of p56lck.
    Macias AT; Mia MY; Xia G; Hayashi J; MacKerell AD
    J Chem Inf Model; 2005; 45(6):1759-66. PubMed ID: 16309282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disubstituted pyrimidines as Lck inhibitors.
    Hunt JA; Beresis RT; Goulet JL; Holmes MA; Hong XJ; Kovacs E; Mills SG; Ruzek RD; Wong F; Hermes JD; Park YW; Salowe SP; Sonatore LM; Wu L; Woods A; Zaller DM; Sinclair PJ
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5440-3. PubMed ID: 19674899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Benzimidazol-2-yl-1H-indazoles as potent c-ABL inhibitors.
    McBride CM; Renhowe PA; Gesner TG; Jansen JM; Lin J; Ma S; Zhou Y; Shafer CM
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3789-92. PubMed ID: 16678414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
    Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
    J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
    Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck.
    Gommermann N; Buehlmayer P; von Matt A; Breitenstein W; Masuya K; Pirard B; Furet P; Cowan-Jacob SW; Weckbecker G
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3628-31. PubMed ID: 20483608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight.
    Burchat AF; Calderwood DJ; Friedman MM; Hirst GC; Li B; Rafferty P; Ritter K; Skinner BS
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1687-90. PubMed ID: 12039591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.